Scarica l'app Stockscreener
2.535
1.00%
0.025
Precedente Chiudi:
$2.51
Aprire:
$2.54
Volume 24 ore:
401.61K
Relative Volume:
0.27
Capitalizzazione di mercato:
$277.58M
Reddito:
-
Utile/perdita netta:
$-134.24M
Rapporto P/E:
-1.4322
EPS:
-1.77
Flusso di cassa netto:
$-121.34M
1 W Prestazione:
+2.63%
1M Prestazione:
+5.19%
6M Prestazione:
-38.17%
1 anno Prestazione:
-59.38%
Intervallo 1D:
$2.50
$2.605
Intervallo di 1 settimana:
$2.325
$2.6784
Portata 52W:
$1.285
$7.85
Annexon Inc Stock (ANNX) Company Profile
Nome
Annexon Inc
Settore
Industria
Telefono
(650)-822-5500
Indirizzo
1400 SIERRA POINT PARKWAY, BRISBANE
Confronta ANNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
2.53 | 275.38M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.86 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.98 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.90 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
596.47 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
297.75 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-01 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-30 | Iniziato | Wells Fargo | Overweight |
| 2023-05-26 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-05-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-09-16 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | BTIG Research | Buy |
| 2021-11-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-09-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-26 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | BofA Securities | Buy |
| 2020-08-18 | Iniziato | Cowen | Outperform |
| 2020-08-18 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Annexon Inc Borsa (ANNX) Ultime notizie
Is Annexon Inc. a growth stock or a value stockNavigate market shifts with confidence - jammulinksnews.com
What markets is CYCC expanding into Is Annexon Inc. stock a good long term investment optionHigh-profit stock alerts - jammulinksnews.com
What are the technical indicators suggesting about Annexon Inc.Achieve rapid wealth accumulation with smart picks - jammulinksnews.com
Is Annexon Inc. a Top Dividend Stock to Watch in 2025Top Momentum Stock Pick - Newser
How Interest Rate Changes Impact Annexon Inc. Stock PerformanceDouble Profit With Half Risk - Newser
What makes Annexon Inc. stock attractive to long term investorsFree Access to Investment Community - Newser
Annexon Inc. Stock Analysis and ForecastOutperformance with explosive growth - PrintWeekIndia
Why Annexon Inc. stock attracts strong analyst attentionProven Trading Plan - Newser
How Annexon Inc. stock performs during market volatilityFree Predictions - Newser
Annexon Announces Completion of Enrollment in Pivotal Phase - GlobeNewswire
Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy - Ophthalmology Times
Annexon completes enrollment in Phase 3 ARCHER II trial - TipRanks
Annexon Announces Completion of Enrollment in Pivotal Phase 3 AR - GuruFocus
Annexon (ANNX) Completes Enrollment for Phase 3 Trial of Vonapru - GuruFocus
Annexon completes enrollment for phase 3 dry AMD therapy trial - Investing.com Australia
Annexon completes enrollment for phase 3 dry AMD therapy trial By Investing.com - Investing.com Nigeria
Annexon, Inc. Completes Enrollment of Phase 3 ARCHER II Trial for Vonaprument, Targeting Vision Preservation in Dry AMD with Geographic Atrophy - Quiver Quantitative
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy - Yahoo Finance
What analysts say about Annexon Inc. stockBreakout portfolio performance - Autocar Professional
Is Annexon Inc. a good long term investmentOutstanding capital returns - jammulinksnews.com
What drives Annexon Inc. stock priceRapidly expanding wealth - jammulinksnews.com
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans? - 富途牛牛
Is Annexon Inc. stock a growth or value playHigh Reward Risk Balanced Trading - Newser
Annexon Inc (ANNX) Stock: A Comprehensive 52-Week Review - investchronicle.com
Annexon EVP Yednock sells $2.9k in shares By Investing.com - Investing.com India
Annexon EVP Yednock sells $2.9k in shares - Investing.com Australia
Annexon Inc Azioni (ANNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):